Renal Biomarkers Market, by Biomarker Type (Functional Biomarker (Serum Creatinine, Serum Cystatin C, Urine Albumin), Up-Regulated Proteins (Neutrophil gelatinase-associated lipocalin, Kidney injury molecule 1, Interleukin 18), Others, By Technique (Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay, Liquid Chromatography-Mass Spectrometry), By End User (Diagnostic Labs, Outpatient Clinics, Research Centers, Hospitals), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) -

Published In : Jul 2023

Code : CMI3551

Pages :145

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Market News

Global Renal Biomarkers Market: Key Developments

In October 2021, (GlaxoSmithKline) GSK, Plc., a multinational pharmaceutical and biotechnology company, showcased significant scientific advances in renal care at the American Society of Nephrology Kidney Week 2021. GSK presented data on BENLYSTA for the treatment of lupus nephritis, including healthcare resource utilization and cost analyses for both lupus nephritis and systemic lupus erythematosus.

On March 17, 2022, the diagnostic company, SphingoTec GmbH (SphingoTec) and Rivaara Labs Pvt Ltd., a development-focused molecular diagnostics company, announced that they have entered into a multi-year distribution agreement for the commercialization of SphingoTec’s point of care diagnostic solutions in the Indian subcontinent. The Nexus IB10 analyzer and its portfolio of rapid tests allow convenient assessment of biomarkers relevant to critical care conditions such as sepsis, acute kidney injury, cardiogenic shock, acute heart failure, and myocardial infarction.

In June 2022, Nordic Bioscience, a biomarker company, announced the strengthening of its ongoing collaboration with F. Hoffmann-La Roche Ltd., a multinational healthcare company for the development of proprietary biomarkers involved in tissue breakdown and build-up. Under the collaboration, Nordic Bioscience will transfer unique and proprietary blood-based biomarkers to Roche Diagnostics to be implemented on the automated COBAS platform. Nordic Bioscience's (Extracellular Matrix) ECM biomarkers are unique and essential for all chronic diseases involving tissue fibrosis inflammation and kidney diseases. The collaboration will facilitate better clinical decisions in drug development and patient selection as well as enrichment for precision medicine and ultimately improve patient outcomes.

In May 2021, Novo Nordisk A/S, a global healthcare company presented results from RESCUE, a phase 2 randomized, double-blind, placebo-controlled clinical trial assessing the effect of once-monthly, investigational ziltivekimab, an interleukin-6 (IL-6) inhibitor, on biomarkers of inflammation. The trial showed a significant reduction of multiple inflammatory biomarkers associated with atherosclerosis in people with advanced chronic kidney disease (CKD) and elevated high-sensitivity C-reactive protein (hsCRP), representing high cardiovascular risk.